Cartilage Repair Market Size, Share, Opportunities, And Trends By Treatment Modality (Cell-Based, Non-Cell-Based), By Application (Hyaline, Fibrocartilage), By Treatment Type (Palliative, Intrinsic Repair Stimulus), By Site (Knee Cartilage Repair, Hip Cartilage Repair, Ankle and Foot Cartilage Repair, Others), And By Geography - Forecasts From 2024 To 2029

The cartilage repair market is experiencing significant growth driven by the rising prevalence of joint-related disorders and injuries worldwide. Cartilage repair procedures are essential for addressing conditions such as osteoarthritis, sports injuries, and trauma that cause damage to cartilage tissue. Innovative techniques such as scaffold implants, autologous chondrocyte implantation, and cell-based therapies are revolutionizing the field of cartilage repair, offering patients effective treatment options to alleviate pain and restore joint function. With advancements in regenerative medicine and increasing awareness about the importance of preserving joint health, the cartilage repair market is poised for continued expansion in the coming years.

Market Drivers

• Rising rate of joint injuries

Young individuals who have experienced knee joint injuries, such as tears in the meniscus or ligaments, are commonly treated for damaged cartilage and often require knee cartilage repair surgery. Procedures like cell-based cartilage resurfacing and the implantation of autologous chondrocytes are utilized to address cartilage damage, promoting the formation of new cartilage within the joints. This not only improves and regenerates cartilage but also significantly reduces joint pain and enhances joint mobility, potentially delaying or preventing the onset of arthritis.

• Prevalence of osteoarthritis

The prevalence of osteoarthritis has been on the rise worldwide in recent years. Research conducted by the University of North Carolina indicates that approximately 1 million knee and hip replacement surgeries are performed annually in the United States alone. The economic burden of osteoarthritis in the United States is significant, costing an estimated $136.8 billion per year. According to the Arthritis Foundation, degenerative joint diseases like osteoarthritis are projected to affect over 130 million individuals globally by the year 2050. Scaffold implants and autologous chondrocyte implantation are among the most widely used treatments for osteoarthritis. Consequently, with the increasing prevalence of osteoarthritis, there is expected to be a rise in demand for products that facilitate cartilage repair and regeneration.

North America is anticipated to hold a significant share of the market-

The North American region is projected to lead the market, driven by the rising prevalence of chronic conditions such as cancer and the introduction of new products. As per the Cancer Statistics 2021 report by the American Cancer Society Journal, approximately 1.9 million new cancer cases and 608,570 cancer-related deaths were recorded in the United States, significantly influencing market growth. Additionally, data from Globocan 2020 indicates that the country had 274,364 new cancer cases in 2020, with projections suggesting an increase to 400,564 by 2040. Therefore, the escalating burden of cancer cases in the country is anticipated to propel market expansion.

Market Developments

• In November 2023, Smith+Nephew revealed its plans to acquire CartiHeal, the creator of Agili-C, an innovative sports medicine technology designed for knee cartilage regeneration. As per the agreement, Smith+Nephew will initially pay $180 million in cash upon completion of the acquisition, with the possibility of an additional $150 million contingent upon financial performance.
• In March 2023, Hy2Care announced that it initiated the next phase of its ACTIVE clinical study to enhance cartilage repair of the knee joint. Following the completion of the first 'safety' group of 10 patients in early 2023, approval was granted by the Medical Ethical Review Committee of the UMC Utrecht to continue the clinical study with the subsequent group of 36 patients. Additionally, the trial was expanded to include the Maastricht UMC+ and the Elisabeth TweeSteden Ziekenhuis in Tilburg, the Netherlands. The CartRevive™ hydrogel implant was developed to facilitate optimal cartilage repair in the knee, addressing a significant unmet clinical need stemming from the widespread prevalence of cartilage repair surgeries worldwide.

Market Segmentation

• By Treatment Modality
  • Cell-Based
  • Non-Cell-Based
• By Application
  • Hyaline
  • Fibrocartilage
• By Treatment Type
  • Palliative
  • Intrinsic Repair Stimulus
• By Site
  • Knee Cartilage Repair
  • Hip Cartilage Repair
  • Ankle and Foot Cartilage Repair
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. CARTILAGE REPAIR MARKET BY TREATMENT MODALITY

5.1. Introduction

5.2. Cell-Based

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.2.3. Chondrocyte Transplantation

5.2.4. Stem Cells

5.2.5. Growth Factor Technology

5.3. Non-Cell-Based

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.3.3. Tissue Scaffolds

5.3.4. Cell-Free Composites

6. CARTILAGE REPAIR MARKET BY APPLICATION

6.1. Introduction

6.2. Hyaline

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.3. Fibrocartilage

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

7. CARTILAGE REPAIR MARKET BY TREATMENT TYPE

7.1. Introduction

7.2. Palliative

7.2.1. Market Opportunities and Trends

7.2.2. Growth Prospects

7.2.3. Viscosupplementation

7.2.4. Debridement & Lavage

7.3. Intrinsic Repair Stimulus

7.3.1. Market Opportunities and Trends

7.3.2. Growth Prospects

8. CARTILAGE REPAIR MARKET BY SITE

8.1. Introduction

8.2. Knee Cartilage Repair

8.2.1. Market Opportunities and Trends

8.2.2. Growth Prospects

8.2.3. Arthroscopic Chondroplasty

8.2.4. Autologous Chondrocyte

8.2.5. Osteochondral Grafts Transplantation

8.2.6. Cell-based Cartilage Resurfacing

8.2.7. Microfracture

8.3. Hip Cartilage Repair

8.3.1. Market Opportunities and Trends

8.3.2. Growth Prospects

8.4. Ankle and Foot Cartilage Repair

8.4.1. Market Opportunities and Trends

8.4.2. Growth Prospects

8.5. Others

8.5.1. Market Opportunities and Trends

8.5.2. Growth Prospects

9. CARTILAGE REPAIR MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. By Treatment Modality

9.2.2. By Application

9.2.3. By Treatment Type

9.2.4. By Site

9.2.5. By Country

9.2.5.1. United States

9.2.5.1.1. Market Opportunities and Trends

9.2.5.1.2. Growth Prospects

9.2.5.2. Canada

9.2.5.2.1. Market Opportunities and Trends

9.2.5.2.2. Growth Prospects

9.2.5.3. Mexico

9.2.5.3.1. Market Opportunities and Trends

9.2.5.3.2. Growth Prospects

9.3. South America

9.3.1. By Treatment Modality

9.3.2. By Application

9.3.3. By Treatment Type

9.3.4. By Site

9.3.5. By Country 

9.3.5.1. Brazil

9.3.5.1.1. Market Opportunities and Trends

9.3.5.1.2. Growth Prospects

9.3.5.2. Argentina

9.3.5.2.1. Market Opportunities and Trends

9.3.5.2.2. Growth Prospects

9.3.5.3. Others

9.3.5.3.1. Market Opportunities and Trends

9.3.5.3.2. Growth Prospects

9.4. Europe

9.4.1. By Treatment Modality

9.4.2. By Application

9.4.3. By Treatment Type

9.4.4. By Site

9.4.5. By Country

9.4.5.1. United Kingdom

9.4.5.1.1. Market Opportunities and Trends

9.4.5.1.2. Growth Prospects

9.4.5.2. Germany

9.4.5.2.1. Market Opportunities and Trends

9.4.5.2.2. Growth Prospects

9.4.5.3. France

9.4.5.3.1. Market Opportunities and Trends

9.4.5.3.2. Growth Prospects

9.4.5.4. Italy

9.4.5.4.1. Market Opportunities and Trends

9.4.5.4.2. Growth Prospects

9.4.5.5. Spain

9.4.5.5.1. Market Opportunities and Trends

9.4.5.5.2. Growth Prospects

9.4.5.6. Others

9.4.5.6.1. Market Opportunities and Trends

9.4.5.6.2. Growth Prospects

9.5. Middle East and Africa

9.5.1. By Treatment Modality

9.5.2. By Application

9.5.3. By Treatment Type

9.5.4. By Site

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.1.1. Market Opportunities and Trends

9.5.5.1.2. Growth Prospects

9.5.5.2. UAE

9.5.5.2.1. Market Opportunities and Trends

9.5.5.2.2. Growth Prospects

9.5.5.3. Others

9.5.5.3.1. Market Opportunities and Trends

9.5.5.3.2. Growth Prospects

9.6. Asia Pacific

9.6.1. By Treatment Modality

9.6.2. By Application

9.6.3. By Treatment Type

9.6.4. By Site

9.6.5. By Country

9.6.5.1. Japan

9.6.5.1.1. Market Opportunities and Trends

9.6.5.1.2. Growth Prospects

9.6.5.2. China

9.6.5.2.1. Market Opportunities and Trends

9.6.5.2.2. Growth Prospects

9.6.5.3. India

9.6.5.3.1. Market Opportunities and Trends

9.6.5.3.2. Growth Prospects

9.6.5.4. South Korea

9.6.5.4.1. Market Opportunities and Trends

9.6.5.4.2. Growth Prospects

9.6.5.5. Taiwan

9.6.5.5.1. Market Opportunities and Trends

9.6.5.5.2. Growth Prospects

9.6.5.6. Thailand

9.6.5.6.1. Market Opportunities and Trends

9.6.5.6.2. Growth Prospects

9.6.5.7. Indonesia

9.6.5.7.1. Market Opportunities and Trends

9.6.5.7.2. Growth Prospects

9.6.5.8. Others

9.6.5.8.1. Market Opportunities and Trends

9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. Smith+ Nephew

11.2. Stryker

11.3. Zimmer Biomet

11.4. B. Braun Melsungen AG

11.5. CONMED Corporation

11.6. Meril Life Sciences Pvt. Ltd.

11.7. Arthrex, Inc.

11.8. Medacta International

11.9. Teijin Nakashima Medical Co., Ltd.

Smith+ Nephew

Stryker

Zimmer Biomet

B. Braun Melsungen AG

CONMED Corporation

Meril Life Sciences Pvt. Ltd.

Arthrex, Inc.

Medacta International

Teijin Nakashima Medical Co., Ltd.